SAN DIEGO, CA, Jan. 25, 2022 (GLOBE NEWSWIRE) — via
Medical Marijuana, Inc.
(OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary
has opened a distribution center in Hong Kong.
“Hemp has a long history in Hong Kong and throughout China,” said Kannaway® CEO Blake Schroeder. “We hope that our streamlined operations will help us continue that legacy and offer our customers with the highest quality, affordable cannabidiol (CBD) products in the region.”
This new distribution center, which houses Kannaway®’s full range of hemp and CBD products, will service the local Hong Kong market and serve as a hub for distribution in the region. Utilizing it will allow for Kannaway® to decrease shipping time and costs substantially in Hong Kong as well as other neighboring countries throughout Asia. This center will serve as a template for the Company to open other distribution centers in other popular market areas around the world.
“Opening this distribution center in Hong Kong is a big commitment in the APAC region and will support our expansion there as well as neighboring countries,” said Kannaway® Chief Sales Officer Peter Dale. “The location provides a much more efficient and less expensive delivery price of our premium products to the emerging markets in Asia.”
To learn more about Kannaway®, please visit the Company online at
is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®
. Medical Marijuana, Inc. (
) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by
; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including
AXIM® Biotechnologies, Inc
. Medical Marijuana, Inc. was named a top CBD producer by
. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product
Real Scientific Hemp Oil
has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at
or by visiting
. To see Medical Marijuana, Inc.’s corporate video,
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations Contact:
Investor Relations Contact:
P. (858) 283-4016